Findings from ImmusanT Provide New Insights into Celiac Disease [Efficacy and Safety of Gluten Peptide-based Antigen-specific Immunotherapy (Nexvax2) In Adults With Coeliac Disease After Bolus Exposure To Gluten (Reset Ced): an Interim Analysis...].

A recent study conducted by ImmusanT in Cambridge, Massachusetts explored the efficacy and safety of a specific immunotherapy called Nexvax2 in treating coeliac disease. The study involved 179 patients with coeliac disease who were randomly assigned to receive either Nexvax2 or a placebo. The results showed that Nexvax2 did not reduce acute gluten-induced symptoms. The study also highlighted the use of a masked bolus vital gluten challenge as an alternative to extended gluten challenge in efficacy studies for coeliac disease. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)